Literature DB >> 22403158

Ochratoxin a and mitotic disruption: mode of action analysis of renal tumor formation by ochratoxin A.

Angela Mally1.   

Abstract

The mycotoxin and food contaminant ochratoxin A (OTA) is a potent renal carcinogen in rodents, but its mode of action (MoA) is still poorly defined. In 2006, the European Food Safety Authority concluded that there is a "lack of evidence for the existence of OTA-DNA adducts" and thus insufficient evidence to establish DNA reactivity as a MoA for tumor formation by OTA. In reviewing the available database on OTA toxicity, a MoA for renal carcinogenicity of OTA is developed that involves a combination of genetic instability and increased proliferative drive as consequences of OTA-mediated disruption of mitosis, whereby the organ- and site-specificity of tumor formation by OTA is determined by selective renal uptake of OTA into the proximal tubule epithelium. The proposed MoA is critically assessed with respect to concordance of dose-response of the suggested key events and tumor formation, their temporal association, consistency, and biological plausibility. Uncertainties, data gaps and needs for further research are highlighted.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22403158     DOI: 10.1093/toxsci/kfs105

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  20 in total

1.  Mycotoxins as human carcinogens-the IARC Monographs classification.

Authors:  Vladimir Ostry; Frantisek Malir; Jakub Toman; Yann Grosse
Journal:  Mycotoxin Res       Date:  2016-11-25       Impact factor: 3.833

2.  A reproductive and developmental screening study of the fungal toxin ochratoxin A in Fischer rats.

Authors:  Genevieve S Bondy; Laurie Coady; Nikia Ross; Don Caldwell; Anne Marie Gannon; Keri Kwong; Stephen Hayward; David E Lefebvre; Virginia Liston; Jayadev Raju; Peter Pantazopoulos; Ivan Curran
Journal:  Mycotoxin Res       Date:  2018-07-04       Impact factor: 3.833

3.  Analyses of biomarkers of exposure to nephrotoxic mycotoxins in a cohort of patients with renal tumours.

Authors:  Frantisek Malir; Miroslav Louda; Vladimir Ostry; Jakub Toman; Nurshad Ali; Yann Grosse; Eva Malirova; Jaroslav Pacovsky; Darina Pickova; Milos Brodak; Annie Pfohl-Leszkowicz; Gisela H Degen
Journal:  Mycotoxin Res       Date:  2019-06-29       Impact factor: 3.833

4.  Inhibition of cytochrome P450 enhances the nephro- and hepatotoxicity of ochratoxin A.

Authors:  Gisela H Degen; Jan G Hengstler; Ahmed Ghallab; Reham Hassan; Daniela González; Zaynab Hobloss; Lisa Brackhagen; Maiju Myllys; Adrian Friebel; Abdel-Latif Seddek; Rosemarie Marchan; Benedikt Cramer; Hans-Ulrich Humpf; Stefan Hoehme
Journal:  Arch Toxicol       Date:  2022-10-13       Impact factor: 6.168

5.  Biomonitoring of concurrent exposure to ochratoxin A and citrinin in pregnant women in Bangladesh.

Authors:  Nurshad Ali; Meinolf Blaszkewicz; M Manirujjaman; Gisela H Degen
Journal:  Mycotoxin Res       Date:  2016-05-17       Impact factor: 3.833

6.  Contribution of organ vasculature in rat renal analysis for ochratoxin a: relevance to toxicology of nephrotoxins.

Authors:  Peter Mantle; Mehmet A Kilic; Firdevs Mor; Ozlem Ozmen
Journal:  Toxins (Basel)       Date:  2015-03-24       Impact factor: 4.546

7.  Evaluating weight of evidence in the mystery of Balkan endemic nephropathy.

Authors:  Travis Bui-Klimke; Felicia Wu
Journal:  Risk Anal       Date:  2014-06-20       Impact factor: 4.000

Review 8.  Comparative Ochratoxin Toxicity: A Review of the Available Data.

Authors:  Alexandra H Heussner; Lewis E H Bingle
Journal:  Toxins (Basel)       Date:  2015-10-22       Impact factor: 4.546

9.  Maternal-Fetal Cancer Risk Assessment of Ochratoxin A during Pregnancy.

Authors:  Chit Shing Jackson Woo; Hani El-Nezami
Journal:  Toxins (Basel)       Date:  2016-03-23       Impact factor: 4.546

Review 10.  Ochratoxin A: Molecular Interactions, Mechanisms of Toxicity and Prevention at the Molecular Level.

Authors:  Tamás Kőszegi; Miklós Poór
Journal:  Toxins (Basel)       Date:  2016-04-15       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.